Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Citius Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CTXR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: CTXR's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: CTXR exceeded the US Pharmaceuticals industry which returned 16.3% over the past year.
Return vs Market: CTXR exceeded the US Market which returned 37.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Citius Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is Citius Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CTXR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CTXR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CTXR is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: CTXR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CTXR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CTXR is good value based on its PB Ratio (2x) compared to the US Pharmaceuticals industry average (2.9x).
How is Citius Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Citius Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Citius Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CTXR is currently unprofitable.
Growing Profit Margin: CTXR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CTXR is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.
Accelerating Growth: Unable to compare CTXR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTXR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.1%).
Return on Equity
High ROE: CTXR has a negative Return on Equity (-16.75%), as it is currently unprofitable.
How is Citius Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: CTXR's short term assets ($105.0M) exceed its short term liabilities ($3.0M).
Long Term Liabilities: CTXR's short term assets ($105.0M) exceed its long term liabilities ($5.9M).
Debt to Equity History and Analysis
Debt Level: CTXR's debt to equity ratio (0.3%) is considered satisfactory.
Reducing Debt: CTXR's debt to equity ratio has reduced from 3.8% to 0.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CTXR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CTXR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 31.6% each year
What is Citius Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CTXR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CTXR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTXR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTXR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTXR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Myron Holubiak (74 yo)
Mr. Myron Z. Holubiak has been the Chief Executive Officer and President of Citius Pharmaceuticals, Inc. since March 30, 2016 and has been its Director since October 1, 2015. Mr. Holubiak served as an Advi...
CEO Compensation Analysis
Compensation vs Market: Myron's total compensation ($USD875.04K) is about average for companies of similar size in the US market ($USD1.11M).
Compensation vs Earnings: Myron's compensation has increased whilst the company is unprofitable.
Experienced Management: CTXR's management team is seasoned and experienced (5.3 years average tenure).
Experienced Board: CTXR's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 220.8%.
Citius Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Citius Pharmaceuticals, Inc.
- Ticker: CTXR
- Exchange: NasdaqCM
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$274.011m
- Shares outstanding: 144.98m
- Website: https://www.citiuspharma.com
Number of Employees
- Citius Pharmaceuticals, Inc.
- 11 Commerce Drive
- First Floor
- New Jersey
- United States
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesen...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/28 02:55|
|End of Day Share Price||2021/07/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.